



*Small, but heading for the big time*

## 2013 ANNUAL RESULTS

**Paris, France, April 11, 2014** – NANObIOTIX (Euronext: NANO–ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces its audited consolidated results for the fiscal year ended December 31, 2013.

*“2013 was a significant eventful year, including major clinical advances for our pipeline of products, NanoXray. The annual results presented today are in line with the development plan and incurred expenditures allowed the delivery of significant milestones in accordance with the commitments made”,* said Laurent Levy, CEO.

- **Income statement**

€	2013 (1)	2012
<b>Total revenue</b>	<b>1,595,466</b>	<b>970,608</b>
Sales	184,938	74,153
Other revenue	1,410,528	896,455
Subsidies	80,973	176,875
Research Tax Credit	1,324,517	718,660
Other	5,038	920
Cost of sales	-	-
R&D costs	(6,025,677)	(4,312,015)
General costs	(3,151,249)	(1,360,225)
Costs associated with payments in shares	(597,958)	(451,196)
<b>Core operating loss</b>	<b>(8,179,418)</b>	<b>(5,152,827)</b>
Financial gain / (charges) (*)	34,497	(99,180)
<b>Core pre-tax loss</b>	<b>(8,144,920)</b>	<b>(5,252,007)</b>
Tax	-	(78,889)
<b>Net loss</b>	<b>(8,126,480)</b>	<b>(5,330,896)</b>

*\* cost of net financial debt and other financial expenses*

*(1) Audit procedures on the individual financial statements prepared under IFRS as adopted by the European Union were performed by the auditors and their certification report will be issued after verification of the management report*

- **Financial Review**

The sole source of revenue to NANObIOTIX corresponds to a pro-rata share of the upfront payment received from its Taiwanese partner, PharmaEngine in August 2012, within the framework of the licensing contract. This contract is for the development and marketing of NBTXR3 in the Asia-Pacific region. In total, the upfront payment totaled €810,640 and the revenue figures have been deferred using the straight-line method between the date the contract was signed and the scheduled marketing launch in the region concerned which is 2017.

For the 12 month period to 31 December 2013, this pro-rata share is €184,938. This figure is in line with the Company's development plan, where the strategy is focused on the development of its NanoXray technology and the marketing of its lead product, NBTXR3.

Total revenue includes subsidies and research tax credit which have increased because of the increase in R&D work during the year.

R&D costs have increased by €1,713,662 in line with the accelerated development of the pipeline, particularly around the progress of the lead product, NBTXR3. This product, which is currently being tested in patients with advanced Soft Tissue Sarcoma (STS), is expected to enter product registration phase (pivotal) by the end of 2014 and thereon, brings forward commercialisation to 2016. The product is also being developed in Head & Neck cancer and, with the support of Bpifrance under a NICE project, is being evaluated with a view to initiating a clinical trial in liver cancer. The NanoXray platform is also being developed in a gel form (NBTX-TOPO) and as an intravenous injection (NBTX-IV).

General and administration costs recorded by the Company increased by €1,791,024 in line with expectations. These costs are mostly due to the purchasing of services, subcontracting costs and personal charges, reflecting recruitment in the operational team in 2013.

The core operating loss was €8,179,418 (FY12: loss €5,152,827).

The financial gain was €34,497 (FY12: charge of €99,180) which corresponds to interest on the bond issue in the short term and costs associated with the restatement of repayable advances.

There was nil tax, and the net loss was €8,126,480.

- **Post year end events**

The Directors of Nanobiotix believe that 2014 is going to be a pivotal year for the Company with respect to the acceleration of the product pipeline and to seeking partners in international markets. To support this, on 25 February 2014, the Company launched a capital increase with preferential subscription rights aiming to raise approximately €24.0 million. The subscription ratio was 3 new shares for 14 existing shares at a subscription price of €10.60 per share. The capital increase was successfully completed on 20 March 2014 and the total amount raised was €28.1 million, after full exercise of the extension clause. The settlement-delivery and the trading of the new shares occurred on 24 March 2014.

The Company is making significant progress in its clinical development, with the right team in place to fulfill the ambitious strategy to make a significant impact in the field of nanomedicine.



***Next financial press release: revenue for Q1 2014 on May 15, 2014.***

**About NANOBIOTIX:** [www.nanobiotix.com](http://www.nanobiotix.com)

Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company's first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat a wide variety of cancers via multiple routes of administration.

Nanobiotix's lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma and locally advanced head and neck cancer. The Company, based in Paris, France, has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.

Nanobiotix is listed on the regulated market of Euronext Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP).

**For more information, please contact:**

---

**Nanobiotix**

**Sarah Gaubert**

*Head of Communication and Public Affairs*

+33 (0)1 40 26 07 55

[contact@nanobiotix.com](mailto:contact@nanobiotix.com)

---

*Financial communication and investors relations*

**NewCap**

**Louis-Victor Delouvrier / Emmanuel Huynh**

+33 (0)1 44 71 98 53

[lvdelouvrier@newcap.fr](mailto:lvdelouvrier@newcap.fr)



---

*Media relations*

France - **NewCap**

**Annie-Florence Loyer / Nadège Le Lezec**

+33 (0)6 88 20 35 59

[afloyer@newcap.fr](mailto:afloyer@newcap.fr) / [nlelezec@newcap.fr](mailto:nlelezec@newcap.fr)

Outside France - **Instinctif Partners** (formerly College Hill)

**Melanie Toyne Sewell / Katherine Lynch / Donia Al Saffar**

+44 (0) 207 457 2020

[nanobiotix@instinctif.com](mailto:nanobiotix@instinctif.com)